A pilot study of the clinical efficacy and safety of memantine for Huntington's disease

Parkinsonism and Related Disorders

Volumn 13, Issue 7, 2007, Pages 453-454

  Ondo, William G ^a   Mejia, Nicte I ^a   Hunter, Christine B ^a  

^a Parkinson's Disease Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMANTINE;

ADULT; BALANCE DISORDER; CHOREA; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DROWSINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HALLUCINATION; HUMAN; HUNTINGTON CHOREA; LETTER; MALE; PRIORITY JOURNAL; SLEEP DISORDER; SOCIOPATHY; SPEECH DISORDER; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIPARKINSON AGENTS; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MEMANTINE; MIDDLE AGED; PILOT PROJECTS; SEVERITY OF ILLNESS INDEX;

EID: 34548814154     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2006.08.005     Document Type: Letter

References (5)

1. Verhagen Metman L., Morris M.J., Farmer C., Gillespie M., Mosby K., Wuu J., et al. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 59 (2002) 694-699
2. Beister A, Kraus P, Kuhn W, Dose M, Weindl A, Gerlach M. The N-methyl-d-aspartate antagonist memantine retards progression of Huntington's disease. J Neural Transm Supp 2004:117-122.
3. Li L., Sengupta A., Haque N., Grundke-Iqbal I., and Iqbal K. Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett 566 (2004) 261-269
4. Kornhuber J., Weller M., Schoppmeyer K., and Riederer P. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl 43 (1994) 91-104
5. Peeters M., Maloteaux J.M., and Hermans E. Distinct effects of amantadine and memantine on dopaminergic transmission in the rat striatum. Neurosci Lett 343 (2003) 205-209